

Board of directors

PETER JOHNSON PHD NON-EXECUTIVE CHAIRMAN

Dr Peter Johnson, age 70, has been a Non-Executive Director of Oxford BioMedica since 1999, and Non-Executive Chairman since January 2001. He has extensive R&D experience with Wellcome, Hoechst, SmithKline, Fisons and Astra. He was formerly Chairman and Managing Director of SmithKline and French Research Ltd. and group main board Director of R&D worldwide for Fisons plc. A former Director of Quadrant Healthcare plc and Proteus Molecular Design Ltd., he is currently a Non-Executive Director of CeNeS Pharmaceuticals plc. He is Chairman of Oxford BioMedica's Audit and Remuneration Committees.

ALAN KINGSMAN MA PHD CHIEF EXECUTIVE OFFICER

Professor Alan Kingsman, age 56, is a co-founder of Oxford BioMedica and has been its Chief Executive Officer since 1996. He is an internationally recognised authority on gene expression and retrovirus research and has over 20 years' experience in this field, including 17 years as co-director (with Susan Kingsman) of the Retrovirus Molecular Biology Group within the Biochemistry department of the University of Oxford. He continues to hold the title of Visiting Professor at Oxford University and is a former fellow of St Catherine's College, Oxford. He has published extensively in the field and is named inventor on numerous patent applications and issued patents. He has acted as an advisor or consultant to UK research councils, WHO and a number of UK and international companies.

ANDREW WOOD CHIEF FINANCIAL OFFICER

Andrew Wood, age 48, has been a Director of Oxford BioMedica since 1996. He is a chartered accountant with wide experience

of financial management in a number of industries. He also holds a first class degree in biochemistry from Oxford University. Before joining Oxford BioMedica he was Finance Director at the Yorkshire Cable Group (part of General Cable plc). Previously, he has held senior financial positions with subsidiaries of the Burton Group (now Arcadia), Associated Newspapers and Fenner.

SUSAN KINGSMAN MA PHD CHIEF SCIENTIFIC OFFICER

Professor Susan Kingsman, age 54, is a co-founder of Oxford BioMedica, and has been a Director of the Company since 1996. She has over 20 years' experience in virology, gene expression and retrovirus biology, including as co-director, with Alan Kingsman, of the Retrovirus Molecular Biology Group at Oxford University. She continues to hold the title of Visiting Professor at Oxford University and is a former fellow of Trinity College, Oxford. She has published extensively in the field and is named inventor on numerous patent applications and issued patents. She advises research councils and research charity committees and has been a consultant for a number of pharmaceutical and biotechnology companies.

MICHAEL MCDONALD MBCHB MRCP CHIEF MEDICAL OFFICER

Dr Mike McDonald, age 54, was appointed to the Board of Oxford BioMedica in February 2006, having joined the Company in September 2005. He has over 20 years' experience in clinical drug development and regulatory leadership. He was previously Chief Medical Officer at Seattle Genetics Inc. and spent nine years with Eli Lilly serving as worldwide Vice President, Clinical Research and Medical Affairs. Before moving to the USA, he was Executive Director of Medical and Regulatory Affairs at Eli Lilly Europe, responsible for all the company's European

regulatory submissions, clinical and health outcomes research and Lilly's European based pharmacovigilance group. He also spent seven years at SmithKline Beecham where he was involved in worldwide clinical development and regulatory management. He received his medical degree from Edinburgh University, is a member of the Royal College of Physicians in London, holds a Diploma in Pharmaceutical Medicine, and is a Fellow of the Faculty of Pharmaceutical Physicians.

PETER NOLAN SENIOR VICE PRESIDENT: COMMERCIAL DEVELOPMENT

Peter Nolan, age 53, was appointed to the Board of Oxford BioMedica in May 2002, having been a senior member of the Company since its foundation. He is also a Director of the UK BioIndustry Association and is a past Chairman of the Oxfordshire Bioscience Network. He has broad experience and knowledge of the biotechnology sector. Prior to joining Oxford BioMedica, he was head of the Biotechnology Unit at the UK Department of Trade & Industry for eight years. In that role he was responsible for establishing and managing complex collaborative research programmes involving industry, research councils and other Government departments. Previously he held senior positions in the Laboratory of the Government Chemist and also the Metropolitan Police Laboratory in London where he was a senior forensic scientist.

NICK WOOLF SENIOR VICE PRESIDENT: CORPORATE STRATEGY

Nick Woolf, age 38, was appointed to the Board of Oxford BioMedica in March 2005, having joined the company in 2002. He has more than eight years' experience as a top-rated biotechnology and pharmaceutical

analyst and has been involved in all aspects of company financing, ranging from initial public offerings to major corporate deals. Prior to joining Oxford BioMedica, he served as Director and Head of European Biotechnology Research at ABN AMRO, where he was responsible for developing its industry coverage. Prior to that, he was Vice President and Senior Analyst at Robertson Stephens and was previously at both Nomura and SBC Warburg. He is a chartered certified accountant and holds a degree in chemistry from Oxford University.

NICK RODGERS
SENIOR INDEPENDENT DIRECTOR

Nick Rodgers, age 48, joined the Board of Oxford BioMedica in March 2004. He is a former investment banker with considerable experience in the life sciences sector. He now works as an independent consultant, having been Head of Life Sciences and joint Head of Corporate Finance at Evolution Beeson Gregory until December 2003. Nick joined Beeson Gregory in 1989 from accountants Ernst & Young, having also worked in the listing department of the London Stock Exchange. He is a member of Oxford BioMedica's Audit and Remuneration Committees.

MARK BERNINGER
NON-EXECUTIVE DIRECTOR

Mark Berninger, age 58, joined the Board of Oxford BioMedica in 1999. He has wide experience in the biotechnology industry in the United States, including as Vice President of Business Development at Genetic Therapy Inc. (GTI). Prior to joining GTI he held a similar position at Gen-Probe Inc. and was Director of Intellectual Property and Technology Acquisition at Life Technologies Inc. between 1989 and 1995. He is currently president and Chief Executive Officer of AnhydroCyte Corporation.

